Sign in or create an account to add this stock to your watchlist.
About Jazz Pharmaceuticals (NASDAQ:JAZZ)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio17.26
Forward P/E Ratio14.16
Sales & Book Value
Annual Sales$1.62 billion
Price / Sales6.12
Cash Flow$13.1385 per share
Price / Cash12.56
Book Value$46.45 per share
Price / Book3.55
EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Return on Equity23.78%
Return on Assets11.97%
Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions
What is Jazz Pharmaceuticals' stock symbol?
Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals (NASDAQ:JAZZ) posted its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing analysts' consensus estimates of $2.73 by $0.15. The specialty pharmaceutical company earned $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a net margin of 26.51% and a return on equity of 23.78%. View Jazz Pharmaceuticals' Earnings History.
When is Jazz Pharmaceuticals' next earnings date?
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?
Jazz Pharmaceuticals updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.00. The company issued revenue guidance of $1.88-1.93 billion, compared to the consensus revenue estimate of $1.89 billion.
What price target have analysts set for JAZZ?
20 brokers have issued 12-month price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $150.00 to $211.00. On average, they expect Jazz Pharmaceuticals' share price to reach $183.0875 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals.
What are Wall Street analysts saying about Jazz Pharmaceuticals stock?
Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)
- 2. Cantor Fitzgerald analysts commented, "JAZZ’s purchase of PRV makes strategic sense to us. This morning, the acquisition of a Priority Review Voucher (PRV) by JAZZ was disclosed. The company is paying $110 million in cash for a PRV owned by Spark Therapeutics (ONCE, Overweight rated covered by Elemer Piros). Particularly when applied to a speed-to-market situation, we believe the PRV could be useful for JAZZ." (4/30/2018)
- 3. According to Zacks Investment Research, "Jazz lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. Xyrem is facing patent challenges in the United States. Jazz has also been facing difficulties in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setback too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market. Shares of the company outperformed the industry in the last one year." (1/12/2018)
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include Regeneron (REGN), Takeda Pharmaceutical (TKPYY), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab (GNMSF), Merck Group (MKGAF) and Perrigo (PRGO).
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the folowing people:
- Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
- Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
- Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
- Dr. Karen L. Smith, Chief Medical Officer and Exec. VP of R&D (Age 50)
- Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)
Has Jazz Pharmaceuticals been receiving favorable news coverage?
Press coverage about JAZZ stock has trended positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jazz Pharmaceuticals earned a news impact score of 0.28 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 45.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Jazz Pharmaceuticals' major shareholders?
Jazz Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.44%), Westfield Capital Management Co. LP (2.01%), Boston Partners (1.78%), FIL Ltd (1.51%), Wells Fargo & Company MN (0.77%) and Amundi Pioneer Asset Management Inc. (0.72%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.
Which major investors are selling Jazz Pharmaceuticals stock?
JAZZ stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., American Century Companies Inc., BlackRock Inc., Boston Partners, KBC Group NV, Royal Bank of Canada, Schroder Investment Management Group and Franklin Resources Inc.. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.
Which major investors are buying Jazz Pharmaceuticals stock?
JAZZ stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Systematic Financial Management LP, Summit Trail Advisors LLC, LSV Asset Management, Baird Financial Group Inc., Point72 Asset Management L.P., Dimensional Fund Advisors LP and Atlantic Trust Group LLC. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals.
How do I buy shares of Jazz Pharmaceuticals?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jazz Pharmaceuticals' stock price today?
One share of JAZZ stock can currently be purchased for approximately $165.02.
How big of a company is Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a market capitalization of $9.81 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.
How can I contact Jazz Pharmaceuticals?
Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]
MarketBeat Community Rating for Jazz Pharmaceuticals (JAZZ)MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Jazz Pharmaceuticals in the last 12 months. Their average twelve-month price target is $183.0875, suggesting that the stock has a possible upside of 10.95%. The high price target for JAZZ is $211.00 and the low price target for JAZZ is $150.00. There are currently 3 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.85||2.81||2.75||2.77|
|Ratings Breakdown: ||0 Sell Rating(s)|
3 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$183.0875||$181.8452||$179.90||$181.0909|
|Price Target Upside: ||10.95% upside||20.20% upside||23.42% upside||33.83% upside|
Jazz Pharmaceuticals (NASDAQ:JAZZ) Consensus Price Target History
Jazz Pharmaceuticals (NASDAQ:JAZZ) Analyst Ratings History
(Data available from 5/26/2016 forward)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 89.23%
Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/15/2018||Matthew P Young||CFO||Sell||1,420||$164.64||$233,788.80||37,623|| |
|5/14/2018||Michael Patrick Miller||EVP||Sell||200||$164.68||$32,936.00||26,122|| |
|5/11/2018||Karen J Wilson||SVP||Sell||3,760||$165.00||$620,400.00||15,811|| |
|5/1/2018||Bruce C Cozadd||CEO||Sell||1,000||$151.57||$151,570.00|| |
|4/16/2018||Matthew P Young||CFO||Sell||700||$156.01||$109,207.00||38,465|| |
|4/13/2018||Michael Patrick Miller||EVP||Sell||200||$157.49||$31,498.00||27,481|| |
|4/10/2018||Karen J Wilson||SVP||Sell||3,899||$155.00||$604,345.00||19,517|| |
|4/2/2018||Bruce C Cozadd||CEO||Sell||1,000||$150.01||$150,010.00||293,542|| |
|3/15/2018||Matthew P Young||CFO||Sell||700||$151.22||$105,854.00||39,165|| |
|3/14/2018||Michael Patrick Miller||EVP||Sell||200||$151.12||$30,224.00||27,681|| |
|3/9/2018||Bruce C Cozadd||CEO||Sell||1,000||$150.00||$150,000.00||294,542|| |
|3/6/2018||Matthew P Young||CFO||Sell||1,152||$142.36||$163,998.72|| |
|3/6/2018||Paul Treacy||SVP||Sell||594||$141.47||$84,033.18|| |
|3/2/2018||Paul Treacy||SVP||Sell||877||$139.62||$122,446.74|| |
|2/28/2018||Bruce C Cozadd||CEO||Sell||1,000||$150.00||$150,000.00||267,468|| |
|2/28/2018||Matthew P Young||CFO||Sell||3,135||$146.85||$460,374.75|| |
|2/14/2018||Michael Patrick Miller||EVP||Sell||200||$139.99||$27,998.00||21,469|| |
|1/16/2018||Matthew P. Young||CFO||Sell||700||$152.16||$106,512.00|| |
|1/12/2018||Bruce C. Cozadd||CEO||Sell||3,000||$150.00||$450,000.00|| |
|1/12/2018||Michael Patrick Miller||EVP||Sell||200||$148.65||$29,730.00||21,669|| |
|12/11/2017||Michael Patrick Miller||EVP||Sell||200||$139.15||$27,830.00|| |
|12/11/2017||Patrick G. Enright||Director||Sell||9,000||$139.73||$1,257,570.00|| |
|11/17/2017||Iain Mcgill||SVP||Sell||8,000||$133.42||$1,067,360.00||28,383|| |
|11/17/2017||Patrick G Enright||Director||Sell||352||$133.19||$46,882.88||1,365|| |
|10/2/2017||Bruce C Cozadd||CEO||Sell||1,000||$150.00||$150,000.00|| |
|9/12/2017||Bruce C. Cozadd||CEO||Sell||1,000||$153.52||$153,520.00|| |
|8/25/2017||Patrick G Enright||Director||Sell||351||$148.40||$52,088.40||1,717|| |
|8/15/2017||Michael Patrick Miller||EVP||Sell||200||$144.38||$28,876.00||21,996|| |
|8/14/2017||Paul Treacy||SVP||Sell||1,304||$143.32||$186,889.28|| |
|8/11/2017||Paul L Berns||Director||Sell||662||$142.37||$94,248.94||6,599|| |
|7/20/2017||Suzanne Sawochka Hooper||EVP||Sell||4,580||$160.00||$732,800.00||32,322|| |
|7/17/2017||Michael Patrick Miller||EVP||Sell||200||$154.97||$30,994.00|| |
|6/23/2017||Suzanne Sawochka Hooper||EVP||Sell||420||$160.00||$67,200.00|| |
|6/15/2017||Michael Patrick Miller||EVP||Sell||200||$150.65||$30,130.00||22,223|| |
|6/1/2017||Rick E Winningham||Director||Sell||5,000||$150.00||$750,000.00||10,391|| |
|5/15/2017||Michael Patrick Miller||EVP||Sell||200||$152.98||$30,596.00||22,623|| |
|5/11/2017||Bruce C Cozadd||CEO||Sell||30,000||$153.47||$4,604,100.00||296,418|| |
|5/9/2017||Suzanne Sawochka Hooper||EVP||Sell||2,500||$160.00||$400,000.00||37,149|| |
|4/27/2017||Karen J Wilson||SVP||Sell||1,275||$160.00||$204,000.00||21,133|| |
|4/27/2017||Suzanne Sawochka Hooper||EVP||Sell||2,500||$160.00||$400,000.00||39,649|| |
|4/17/2017||Michael Patrick Miller||SVP||Sell||200||$152.56||$30,512.00||22,562|| |
|4/11/2017||Bruce C Cozadd||CEO||Sell||1,000||$152.12||$152,120.00||308,491|| |
|4/10/2017||Karen J Wilson||SVP||Sell||11,458||$152.24||$1,744,365.92||27,158|| |
|3/15/2017||Michael Patrick Miller||SVP||Sell||200||$137.89||$27,578.00||22,762|| |
|3/6/2017||Paul Treacy||SVP||Sell||884||$131.97||$116,661.48||18,108|| |
|2/15/2017||Michael Patrick Miller||SVP||Sell||200||$134.55||$26,910.00||16,486|| |
|1/18/2017||Russell J. Cox||COO||Sell||4,000||$128.75||$515,000.00|| |
|1/17/2017||Michael Patrick Miller||SVP||Sell||200||$115.93||$23,186.00||16,686|| |
|12/15/2016||Michael Patrick Miller||SVP||Sell||200||$103.09||$20,618.00|| |
|12/2/2016||Patrick G Enright||Director||Sell||677||$101.80||$68,918.60||1,365|| |
|11/15/2016||Michael Patrick Miller||SVP||Sell||200||$112.19||$22,438.00||16,925|| |
|11/14/2016||Kenneth W O'keefe||Director||Buy||2,000||$113.84||$227,680.00||12,107|| |
|10/17/2016||Michael Patrick Miller||SVP||Sell||200||$118.16||$23,632.00||17,125|| |
|9/19/2016||Michael Patrick Miller||SVP||Sell||200||$126.17||$25,234.00||17,325|| |
|8/25/2016||Seamus Mulligan||Director||Sell||27,968||$128.32||$3,588,853.76||1,072,411|| |
|8/16/2016||Paul Treacy||SVP||Sell||1,292||$137.47||$177,611.24|| |
|8/15/2016||Michael Patrick Miller||SVP||Sell||100||$136.45||$13,645.00||17,525|| |
|8/15/2016||Rick E Winningham||Director||Sell||633||$136.45||$86,372.85||15,391|| |
|8/12/2016||Karen L Smith||Insider||Buy||608||$137.10||$83,356.80||14,181|| |
|8/9/2016||Bruce C. Cozadd||CEO||Sell||1,000||$150.00||$150,000.00|| |
|8/9/2016||Russell J. Cox||COO||Sell||4,000||$148.66||$594,640.00|| |
|7/15/2016||Michael Patrick Miller||SVP||Sell||100||$142.43||$14,243.00||17,625|| |
|7/13/2016||Karen L Smith||CMO||Buy||580||$143.63||$83,305.40||13,574|| |
|6/15/2016||Michael Patrick Miller||SVP||Sell||100||$149.64||$14,964.00||17,725|| |
|6/13/2016||Karen L Smith||CMO||Buy||557||$149.61||$83,332.77||12,994|| |
|5/16/2016||Heather Ann Mcsharry||Director||Sell||697||$145.20||$101,204.40||5,396|| |
|5/16/2016||Michael Patrick Miller||SVP||Sell||100||$145.20||$14,520.00||17,753|| |
|4/25/2016||Karen J Wilson||SVP||Sell||604||$160.00||$96,640.00||18,059|| |
|4/15/2016||Michael Patrick Miller||SVP||Sell||100||$145.79||$14,579.00||18,792|| |
|4/13/2016||Karen J Wilson||SVP||Sell||5,007||$150.00||$751,050.00||18,663|| |
|4/12/2016||Russell J Cox||COO||Sell||4,000||$136.98||$547,920.00||60,470|| |
|4/7/2016||Karen J Wilson||SVP||Sell||2,161||$140.90||$304,484.90||23,670|| |
|3/15/2016||Michael Patrick Miller||SVP||Sell||100||$129.17||$12,917.00||18,892|| |
|3/8/2016||Bruce C Cozadd||CEO||Sell||2,500||$126.04||$315,100.00||302,566|| |
|2/29/2016||Paul Treacy||SVP||Sell||354||$123.48||$43,711.92||15,102|| |
|2/23/2016||Seamus Mulligan||Director||Sell||27,968||$122.71||$3,431,953.28||1,127,831|| |
|2/16/2016||Michael Patrick Miller||SVP||Sell||100||$115.63||$11,563.00||13,461|| |
|2/10/2016||Patrick G Enright||Director||Sell||10,000||$117.92||$1,179,200.00||1,310|| |
|2/9/2016||Bruce C Cozadd||CEO||Sell||2,500||$111.37||$278,425.00||281,896|| |
|1/15/2016||Michael Patrick Miller||SVP||Sell||100||$122.66||$12,266.00||13,561|| |
|1/12/2016||Bruce C Cozadd||CEO||Sell||2,500||$123.81||$309,525.00||284,396|| |
|1/5/2016||Patrick G Enright||Director||Sell||10,000||$138.09||$1,380,900.00||1,310|| |
|12/15/2015||Michael Patrick Miller||SVP||Sell||100||$136.99||$13,699.00||13,661|| |
|12/8/2015||Bruce C Cozadd||CEO||Sell||2,500||$139.72||$349,300.00||286,855|| |
|12/2/2015||Patrick G Enright||Director||Sell||10,424||$146.67||$1,528,888.08||1,310|| |
|11/23/2015||Seamus Mulligan||Director||Sell||27,968||$145.86||$4,079,412.48||1,130,547|| |
|11/10/2015||Bruce C Cozadd||CEO||Sell||2,500||$128.53||$321,325.00||289,355|| |
|11/10/2015||Patrick G Enright||Director||Sell||10,000||$135.29||$1,352,900.00||1,734|| |
|10/21/2015||Suzanne Sawochka Hooper||EVP||Sell||2,000||$125.00||$250,000.00||35,855|| |
|10/13/2015||Bruce C Cozadd||CEO||Sell||2,500||$131.50||$328,750.00||291,855|| |
|10/5/2015||Patrick G Enright||Director||Sell||10,000||$133.79||$1,337,900.00||1,734|| |
|9/25/2015||Michael Patrick Miller||SVP||Sell||100||$145.23||$14,523.00||13,890|| |
|9/8/2015||Bruce C. Cozadd||CEO||Sell||2,500||$163.07||$407,675.00||294,355|| |
|9/1/2015||Patrick G Enright||Director||Sell||10,000||$165.99||$1,659,900.00||1,734|| |
|7/14/2015||Bruce C Cozadd||CEO||Sell||5,000||$177.79||$888,950.00|| |
|7/14/2015||Suzanne Sawochka Hooper||EVP||Sell||4,000||$177.79||$711,160.00|| |
|7/6/2015||Patrick G Enright||Director||Sell||10,000||$177.11||$1,771,100.00|| |
|6/9/2015||Bruce C Cozadd||CEO||Sell||5,000||$173.16||$865,800.00|| |
|6/9/2015||Suzanne Sawochka Hooper||EVP||Sell||4,000||$173.16||$692,640.00|| |
|6/2/2015||Karen J Wilson||SVP||Sell||5,751||$179.59||$1,032,822.09|| |
|6/1/2015||Karen J Wilson||SVP||Sell||5,494||$179.57||$986,557.58|| |
|4/14/2015||Bruce C Cozadd||CEO||Sell||5,000||$181.45||$907,250.00|| |
|4/14/2015||Suzanne Sawochka Hooper||EVP||Sell||4,000||$181.45||$725,800.00|| |
|3/25/2015||Seamus Mulligan||Director||Sell||50,000||$174.59||$8,729,500.00|| |
|1/5/2015||Patrick G Enright||Director||Sell||10,000||$160.25||$1,602,500.00|| |
|12/26/2014||Seamus Mulligan||Director||Sell||50,000||$163.40||$8,170,000.00|| |
|12/12/2014||Patrick G Enright||Director||Sell||2,343||$170.98||$400,606.14|| |
|12/9/2014||Bruce C Cozadd||CEO||Sell||5,000||$178.79||$893,950.00|| |
|12/9/2014||Suzanne Sawochka Hooper||EVP||Sell||1,852||$178.79||$331,119.08|| |
|12/1/2014||Patrick G Enright||Director||Sell||10,000||$172.74||$1,727,400.00|| |
|11/24/2014||Jeffrey K Tobias||CMO||Sell||4,598||$170.12||$782,211.76|| |
|11/7/2014||Iain Mcgill||SVP||Sell||7,066||$172.03||$1,215,563.98|| |
|10/10/2014||Jeffrey K Tobias||CMO||Sell||1,000||$154.04||$154,040.00|| |
|10/6/2014||Patrick G Enright||Director||Sell||10,000||$160.56||$1,605,600.00|| |
|9/25/2014||Seamus Mulligan||Director||Sell||50,000||$163.16||$8,158,000.00|| |
|9/24/2014||Seamus Mulligan||Director||Sell||35,294||$163.70||$5,777,627.80|| |
|9/12/2014||Jeffrey K Tobias||CMO||Sell||1,000||$171.22||$171,220.00|| |
|9/11/2014||Karen J Wilson||SVP||Sell||3,000||$175.00||$525,000.00|| |
|9/11/2014||Seamus Mulligan||Director||Sell||50,000||$175.00||$8,750,000.00|| |
|9/9/2014||Bruce C Cozadd||CEO||Sell||5,000||$170.32||$851,600.00|| |
|9/8/2014||Karen J Wilson||SVP||Sell||2,500||$170.00||$425,000.00|| |
|9/8/2014||Suzanne Sawochka Hooper||EVP||Sell||1,852||$168.00||$311,136.00|| |
|8/12/2014||Bruce C Cozadd||CEO||Sell||5,000||$133.15||$665,750.00|| |
|8/12/2014||Suzanne Sawochka Hooper||EVP||Sell||1,185||$133.15||$157,782.75|| |
|8/11/2014||Jeffrey K Tobias||CMO||Sell||4,933||$135.42||$668,026.86|| |
|7/8/2014||Bruce C Cozadd||CEO||Sell||5,000||$155.00||$775,000.00|| |
|7/8/2014||Suzanne Sawochka Hooper||EVP||Sell||1,853||$155.00||$287,215.00|| |
|7/7/2014||Karen J Wilson||SVP||Sell||2,500||$165.00||$412,500.00|| |
|6/25/2014||Seamus Mulligan||Director||Sell||50,000||$149.69||$7,484,500.00|| |
|6/20/2014||Russell J Cox||COO||Sell||2,000||$155.00||$310,000.00|| |
|6/17/2014||Fintan Keegan||EVP||Sell||3,750||$150.00||$562,500.00|| |
|6/10/2014||Bruce C Cozadd||CEO||Sell||5,000||$142.34||$711,700.00|| |
|5/16/2014||Jeffrey Tobias||CMO||Sell||1,000||$128.01||$128,010.00||47,103|| |
|5/13/2014||Bruce Cozadd||CEO||Sell||5,000||$128.92||$644,600.00||606,810|| |
|4/17/2014||Rick Winningham||Director||Sell||27,500||$140.00||$3,850,000.00||13,587|| |
|4/14/2014||Jeffrey Tobias||CMO||Sell||3,000||$128.54||$385,620.00||48,103|| |
|4/8/2014||Bruce Cozadd||CEO||Sell||5,000||$123.18||$615,900.00||611,810|| |
|3/10/2014||Jeffrey Tobias||CMO||Sell||3,000||$152.99||$458,970.00||48,103|| |
|3/6/2014||Fintan Keegan||EVP||Sell||4,640||$159.90||$741,936.00||39,272|| |
|3/4/2014||Seamus Mulligan||Director||Sell||550,000||$156.25||$85,937,500.00||1,455,555|| |
|3/3/2014||Patrick Enright||Director||Sell||559,628||$152.39||$85,281,710.92|| |
Jazz Pharmaceuticals (NASDAQ JAZZ) News Headlines
Jazz Pharmaceuticals (NASDAQ:JAZZ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Jazz Pharmaceuticals (NASDAQ:JAZZ) Income Statement, Balance Sheet and Cash Flow Statement
Jazz Pharmaceuticals (NASDAQ JAZZ) Stock Chart for Saturday, May, 26, 2018